vTv Therapeutics Inc Class A VTVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VTVT is a good fit for your portfolio.
News
-
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
-
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
-
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
-
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
-
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
-
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
Trading Information
- Previous Close Price
- $24.74
- Day Range
- $23.81–24.21
- 52-Week Range
- $7.72–39.60
- Bid/Ask
- $20.00 / $24.75
- Market Cap
- $58.49 Mil
- Volume/Avg
- 3,519 / 76,595
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.vtvtherapeutics.com
Comparables
Valuation
|
Metric
|
VTVT
|
MRNS
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 4.59 | 3.30 |
Price/Sales | — | 2.45 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VTVT
MRNS
ICVX
Financial Strength
|
Metric
|
VTVT
|
MRNS
|
ICVX
|
|---|---|---|---|
Quick Ratio | 0.90 | 3.79 | 17.59 |
Current Ratio | 1.00 | 4.07 | 18.06 |
Interest Coverage | −2,032.69 | −7.94 | — |
Quick Ratio
VTVT
MRNS
ICVX
Profitability
|
Metric
|
VTVT
|
MRNS
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −107.66% | −59.45% | −29.30% |
Return on Equity (Normalized) | — | −195.80% | −31.87% |
Return on Invested Capital (Normalized) | — | −84.00% | −34.69% |
Return on Assets
VTVT
MRNS
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yvjcgtbzr | Jkm | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qsqyzqx | Gwbsj | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zbngnlqf | Xlvddbl | $98.1 Bil | |
MRNA
| Moderna Inc | Pmzjvfhz | Rtv | $39.1 Bil | |
ARGX
| argenx SE ADR | Tjkgtrnb | Gkm | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Jlstmjkg | Ftykg | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jgwjlrrx | Zsccw | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rhznwnrnw | Mmjmd | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wpvxstcrv | Mssxcrf | $12.5 Bil | |
INCY
| Incyte Corp | Stxnfytv | Vxywb | $11.9 Bil |